Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_assertion type Assertion NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_head.
- NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_assertion description "[In contrast to tissue testing, which is a one-time event, monitoring the circulating levels of the HER2/neu ECD in patients with breast cancer provides a real-time assessment of the HER2/neu status and provides important information for managing the therapy of patients with MBC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_provenance.
- NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_assertion evidence source_evidence_literature NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_provenance.
- NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_assertion SIO_000772 15245613 NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_provenance.
- NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_assertion wasDerivedFrom befree-20140225 NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_provenance.
- NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_assertion wasGeneratedBy ECO_0000203 NP236629.RAoYLEGQo1xUTDq-PMBFn_SlSVwzlJQSnf6Yl2sxnOAEc130_provenance.